



#21
IDS
Patent
Attorney
Docket #044508-5001
A. 26.03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: **Gerald Quinnan, Jr. et al.**)
Application No. **09/762,261**) Art Unit: **1653**
Filed: **February 5, 2001**) Examiner: **Shanon Foley**
For: **Expression and Characterization of HIV-1**)
Envelope Protein Associated With a Broadly)
Reactive Neutralizing Antibody Response)

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.97(d)

Pursuant to 37 C.F.R. 1.56 and 1.97(d), Applicants bring to the attention of the Examiner the documents listed on the attached PTO-1449. This Information Disclosure Statement is being filed, to the best of the undersigned's knowledge, after the mailing of a Final Office Action but before issuance of a Notice of Allowance. Under the provisions of 37 C.F.R. 1.97(d), a fee of \$180.00 as specified by 1.17(d) is required for the filing of this Information Disclosure Statement. The Commissioner is hereby authorized to charge **\$180.00** to Deposit Account No. 50-0310 for payment of the Information Disclosure Statement fee as set forth on the accompanying transmittal form.

Copies of the listed documents are attached. Documents aa through ah were cited in a Supplemental Search Report which issued in a corresponding European Patent Application. A copy of the Supplemental European Search report is also attached.

Applicants respectfully request that the Examiner consider the listed documents and evidence that consideration by making appropriate notations on the attached form. This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that the above-listed documents are material or constitute prior art. If the Examiner applies the documents as prior art against any claim in the application and Applicants determine that the cited document does not constitute prior art under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such document.


Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the application and the references therein, should one or more of the documents be applied against the claims of the present application.

Except for issue fees payable under 37 C.F.R. 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. 1.16 and 1.17 which may be required, including any required extension of time fees, or

credit any overpayment to Deposit Account 50-0310. This paragraph is intended to be a **constructive petition for extension of time** in accordance with 37 C.F.R. 1.136(a)(3).

Dated: **September 11, 2003**
Morgan, Lewis & Bockius LLP
Customer No. **09629**
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
202-739-3000

Respectfully submitted
Morgan, Lewis & Bockius LLP



Robert Smyth
Registration No. 50,801